经济新闻
中国药企华海药业与西班牙Almirall签署3.4亿美元协议后股价上涨 2026-03-30
Huahai Pharmaceutical’s shares gained after the Chinese drugmaker said a deal with Spanish dermatology specialist Almirall could bring in royalty payments of USD340 million.
Huahai Pharma closed 2.3 percent higher at CNY16.18 (CNY2.34) per share in Shanghai on March 30, after earlier climbing by as much as 3.4 percent.
Shanghai Huaota Biopharmaceutical, a unit of Taizhou-based Huahai, has reached a global research and licensing agreement with Almirall to develop a new-targeted monoclonal antibody candidate for skin diseases and other potential uses, it announced late on March 27.
Under the deal, Almirall will pay Huaota as much as USD340 million in licensing fees tied to drug development, regulatory approval, and commercial sales, including an upfront payment, as well as milestone payments linked to clinical trials, new drug registration, and commercialization.
Huaota keeps the China rights, while Almirall gets the rights outside of the country. After the new drug reaches the market, both parties will also receive royalties from each other’s respective sales, according to an agreed-upon percentage.
Chinese drugmakers are attracting more cross-border deals as their capabilities strengthen. In the first quarter, outbound licensing deals for China’s innovative drugs topped USD60 billion, already close to half of last year’s total, an official with the National Medical Products Administration said at a forum last week.
Barcelona-based Almirall is a global dermatological drugmaker whose products are sold in more than 100 countries, Huahai said.
Huahai is primarily a generics maker, but through Huaota it has been building a pipeline in biologics and novel treatments, with programs spanning oncology, autoimmune disease, and ophthalmology. Huaota is one of the few Chinese drugmakers with full-chain research abilities, from early development to pilot production.
Source: Yicai Global
